-+ 0.00%
-+ 0.00%
-+ 0.00%

Amgen (AMGN) Could Be 42% Below Fair Value After Fresh Trial Results

Simply Wall St·11/16/2026 19:12:53
Listen to the news

Amgen (AMGN) is back in focus after a cluster of trial updates, including real-world and Phase 3 data for Repatha and new Phase 3 results for dazodalibep in Sjögren's disease, which have sharpened attention on its pipeline.

The stream of trial news has arrived alongside a strong run in Amgen’s shares, with a 30-day share price return of 7.67% and a year-to-date share price gain of 42.13%. The 5-year total shareholder return of 166.13% points to momentum that has been building over a longer stretch as investors factor in both current earnings delivery and perceived pipeline potential.

Scan how Amgen’s recent trial momentum compares with other large-cap healthcare players by reviewing the hand-picked 30 resilient stocks with low risk scores with resilient balance sheets and steadier risk profiles.

After a 42% year-to-date climb and a string of encouraging trial readouts, Amgen now asks a harder question for new capital: Do current expectations already fully reflect that momentum, or is there still a margin of safety in the valuation?

Most Popular Narrative: 29% Overvalued

Amgen last closed at $465.67, while the most followed narrative on Simply Wall St assigns a fair value of $359.98. This implies the shares trade at a premium and invites closer scrutiny of what is being priced in.

According to AnimalDoctorKwon, an investor in the Simply Wall St Community who wrote the narrative, the current enthusiasm around Amgen is tightly linked to expectations in obesity and regulatory fast-track tailwinds rather than the stability of the existing portfolio.

Here is the cold, data-driven reality:

1. CNPV solves regulatory speed, not the manufacturing bottleneck. Amgen lacks the massive, domestic GLP-1 supply chain infrastructure that Lilly and Novo command. Fast-tracked approval without scale-up capacity only accelerates market-share caps.

See why 8 investors see Amgen as 29% overvalued.

Result: Fair Value of $359.98 (OVERVALUED)

Still, if Amgen executes on obesity manufacturing capacity sooner than expected, or stabilizes erosion in products like Enbrel and Prolia, this bearish narrative could unravel quickly.

Find out about the key risks to this Amgen narrative.

Another View On Amgen’s Valuation

That community narrative leans on a fair value of $359.98, yet the SWS DCF model points a different way. On this cash flow view, Amgen at $465.67 trades 42.4% below an estimated future cash flow value of $809.02, which presents one perspective that current pricing may be undervalued. Which story feels more convincing to you?

For investors who want to see how this cash flow view is built line by line, Look into how the SWS DCF model arrives at its fair value.

AMGN Discounted Cash Flow as at Nov 2026
AMGN Discounted Cash Flow as at Nov 2026

Next Steps

Conflicted by the split between bullish and cautious views on Amgen. Move quickly to stress test both perspectives and weigh the 4 key rewards and 1 important warning sign

Looking for more ideas beyond Amgen?

Do not stop your research with Amgen when a wider universe of opportunities might fit your goals just as well, or even better.